Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dhruvajyoti Roy is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner within 1 distinct art unit. The singular nature of this activity suggests a specific focus for the current patent filings, with all activity concentrated in one administrative group at the patent office.
The busiest examiner, JONES, CHRISTINE MICHELLE, is assigned 1 pending office action. This single action constitutes the total number of pending office actions for the portfolio. With only 1 distinct art unit involved, the prosecution is subject to the standards of one specific administrative group. Practitioners should analyze the specific requirements of JONES, CHRISTINE MICHELLE to successfully navigate this Biotechnology & Pharmaceuticals case.
Because the busiest examiner, JONES, CHRISTINE MICHELLE, handles the 1 pending office action, there is no internal data to compare examiner behavior within the portfolio. The presence of 1 distinct examiner and 1 distinct art unit creates a centralized prosecution environment. Success for this portfolio depends on tailoring the approach to the specific requirements and interpretive style of this single official in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555711 | LIVER CANCER METHYLATION AND PROTEIN MARKERS AND THEIR USES | JONES, CHRISTINE MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18555711 | LIVER CANCER METHYLATION AND PROTEIN MARKERS AND THEIR USES | JONES, CHRISTINE MICHELLE | 1682 | §101§102§112DP | Non-Final OA | — | Pending | Oct 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDhruvajyoti Roy has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christine Michelle Jones has the most, with 1 of Dhruvajyoti Roy's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
